<DOC>
	<DOC>NCT00977210</DOC>
	<brief_summary>The purpose of this study is to establish the Maximum Tolerated Dose (MTD) of OXi4503 given by weekly infusions to patients with advanced solid tumors.</brief_summary>
	<brief_title>Safety Study of OXi4503 (a Vascular Disrupting Agent) Given by 3 x Weekly Intravenous Infusions to Patients With Advanced Solid Tumors</brief_title>
	<detailed_description />
	<criteria>Histologically proven cancer. Written informed consent. Age &gt;/= 18 years. Life expectancy of at least 12 weeks. World Health Organization (WHO) performance status of 0 or 1. Adequate Hematological and biochemical indices to support investigational therapy. All women of childbearing potential (WOCBP) must have a negative serum pregnancy test. WOCBP and fertile men and their partners must agree to use an effective form of contraception during the study and for 90 days after the last dose of study medication. Measurable and evaluable disease. All toxic manifestations of previous treatment must have resolved. Able to undergo MRI scanning. Radiotherapy, endocrine therapy, immunotherapy or chemotherapy during the previous four weeks (six weeks for nitrosureas and MitomycinC) prior to treatment. Pregnant and lactating women. Major thoracic and/or abdominal surgery in the preceding four weeks from which the patient has not yet recovered. Patients which have active uncontrolled infections. Patients with any other condition that in the Investigator's opinion would not make the patient a good candidate for the clinical trial. Patients known to be serologically positive for Hepatitis B, Hepatitis C or Human Immunodeficiency Virus (HIV). Previous or ongoing cardiac conditions. Uncontrolled hypertension. Patients taking any drug known to prolong the QTc interval. Patients who have had any ischaemic or vascular damage from previous radiotherapy. Patients taking warfarin or heparin. Patients taking naproxen. Patients taking supplements or multivitamins containing vitamin C. Patients should not be taking any other investigational drug for the duration of the study. Patients with brain metastases or neurological tissue involvement of the spinal column.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2011</verification_date>
	<keyword>Phase 1</keyword>
	<keyword>oxi4503</keyword>
	<keyword>oxigene</keyword>
	<keyword>cruk</keyword>
	<keyword>solid tumors</keyword>
	<keyword>VDA</keyword>
	<keyword>vascular disrupting agent</keyword>
</DOC>